



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




LMB763

Item No. 30184

CAS Registry No.: 1773489-72-7
Formal Name: 4-[[[(8-chloro-1,4-dihydro-1-methyl[1]benzopyrano[4,3-c]pyrazol-3-yl)carbonyl](phenylmethyl)amino]methyl]-benzoic acid

Synonym: Nidufexor
MF: C₂₇H₂₂ClN₃O₄
FW: 487.9
Purity: ≥98%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LMB763 is supplied as a solid. A stock solution may be made by dissolving the LMB763 in the solvent of choice, which should be purged with an inert gas. LMB763 is soluble in organic solvents such as ethanol and DMSO.

Description

LMB763 is a partial agonist of the farnesoid X receptor (FXR; EC₅₀ = 7 nM).¹ It is selective for FXR over a panel of enzymes, ion channels, nuclear receptors, and G protein-coupled receptors, including the androgen receptor, estrogen receptor α (ERα), and G protein-coupled bile acid receptor 1 (GPBAR1; EC₅₀s = >30, >30, and >80 μM, respectively). LMB763 induces expression of the FXR target genes encoding the bile salt export pump and short heterodimer partner in isolated rat hepatocytes in a concentration-dependent manner. It decreases non-alcoholic fatty liver disease (NAFLD) scores and liver fibrosis in a rat model of non-alcoholic steatohepatitis (NASH).

Reference

1. Chianelli, D., Rucker, P.V., Roland, J., *et al.* Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis (NASH). *J. Med. Chem.* **63**(8), 3868-3880 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/02/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM